 |
 |
Date Announced: 19 Feb 2013
Switzerland Has Third Highest Skin Cancer Rate in the World.
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 19, 2013) - Verisante Technology, Inc., a leader in cancer detection technology, announced today that the Company has entered into an exclusive agreement with Pacifica Handels AG to distribute Verisante Aura™ in Switzerland.
"Pacifica Handels AG is an award-winning distributor of medical devices in Switzerland," said Thomas Braun, President & CEO of Verisante. "Pacifica knows the market for dermatological and skin care devices in Switzerland intimately, and this specialized knowledge in a country that has the third highest skin cancer rate in the world will be extremely helpful with market penetration. Pacifica will distribute Aura™ and also support technical training and servicing in Switzerland."
Pacifica is based in Baar, Switzerland and distributes innovative products for the world's leading global manufacturer of medical laser and IPL™ systems for use in aesthetics, dermatology, and other applications. Aura™ is a complementary addition to the Company's existing product line.
"There is an epidemic of skin cancer in Switzerland," said Dr. Heiner Grönewald, Managing Director of Pacifica. "Aura's™ impressive clinical study results show it can quickly and accurately assist in skin cancer diagnosis, and I am confident this tool will be welcomed by doctors and clinics across Switzerland."
The European medical device market is the second largest in the world, worth over $78 billion and representing 30 per cent of the world market - second only to the United States. Switzerland has a population of nearly 8 million people, and 400 dermatologists serving the country.
According to the Swiss Federal Health Office, Switzerland has the third highest skin cancer rate in the world behind Australia and New Zealand, and has more new melanoma cases per year than any other country in Europe, with 22 new cases recorded annually for every 100,000 people. Over the last 20 years, cases of malignant melanoma in Switzerland have doubled and in 30 percent of cases, melanoma occurs in people before they reach the age of 50.
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.
Source: Verisante Technology
E-mail: info@verisante.com
Web Site: www.verisante.com
| © 2024 SPIE Europe |
|
